Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can you stick the news? Thanks bro
he who laughs last laughs best
Like all new biotech companies, isn't it?
I'm agree ;)
Bod must be in prison..
Only a sob or a mm can sell under 1 usd.
Agree!!
Any moderator can stick that info? Thanks
longs will be rewarded. the company is doing an excellent work.
Goooooo
Wow!!! ;)
Everyday??
higher lows and lower highs. Up we go
another hit for Hemaxellerate on FDA Two hours ago..
you are welcome, I'm happy for all the ENTB shareholders.
Noooo!!
From spain, don't waste your time...
-12,5% with only 450 sells...
No one will sell... i have my tikets to paradise. Over 3 usd before eoy. IMO GOOOO
Yes!! Nice
Here for example.... You don't say buy you are trying
"Another FDA Hemaxellerate hit. Most likely FDA confirmation of rejection with even more questions for the company to answer. Sorry guys. Kiss your money"
I couldn't have said it better myself.
I hope that he cares...
till then MM will try to scare weak hands
No volume. Shares in strong hands and mm playing with 100.000 - 200.000 shares...
Lol... In your dreams!
Pump and dump lol... You are very funny.
Regen Receives Green Light From FDA to Proceed With GLP Safety Study in Support of Its HemaXellerate Investigational New Drug Application
Company Believes GLP Safety Study Is the Last Hurdle for HemaXellerate IND
SAN DIEGO, CA--(Marketwired - Mar 17, 2015) - Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that it has received final comments and authorization from the FDA to proceed with its GLP Safety Study in support of the company's HemaXellerate Investigational New Drug application (IND) which is on file with the FDA.
Dr. Thomas Ichim stated, "The FDA has reviewed our protocols for the GLP Safety Study. They made several comments which have been incorporated into our protocols. The next step is for Regen to commence this study. Once completed, the results will be presented to the FDA. We believe that this process represents the last hurdle for Regen's HemaXellerate IND to clear before we are allowed to move into clinical trials."
Lol... I will remember this post...
we are very close from FDA approval and RGBP will be trading over 3USD with this low float... the train is leaving the station.
I like the new version of kfox 2.0
Like angel...
Back to 0,30 - 0,40 range
rgbp
Regen BioPharma, Inc. Successfully Completes in Life Portion of Experiments Requested by FDA for HemaXellerate Pre-Clinical Study
Company anticipates pre-clinical study to lead to clearance of its Aplastic Anemia Therapy (IND # 15376) for clinical trials
PR Newswire Regen BioPharma, Inc.
50 minutes ago
SAN DIEGO, California, Jul. 21, 2015 /PRNewswire/ -- Regen BioPharma Inc. (RGBP) and (RGBP) announced today positive preliminary safety results from the in life portion of an experimental study requested by the US Food and Drug Administration (FDA) assessing toxicity in mice treated with high doses of HemaXellerate, a proprietary therapy under development by Regen Biopharma, Inc. After a 14 day observation period, male and female mice administered with higher than 10-fold the proposed human dose on a per kilogram basis exhibited no adverse effects. Regen expects to receive an audited report on full completion of the experiments in mid-September.
"The fact that no adverse effects related to HemaXellerate administration were observed during the in life portion of this study, even at extremely high doses, in my opinion is a very strong confirmation of the safety of our product," said Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma. "We are impressed with the diligence, expedience, and thoroughness that Charles River Laboratories exhibited in conducting this study."
The experiment is being conducted under Good Laboratory Practices (cGLP) by Charles River Laboratories. Charles River Laboratories, established in 1947, is a well respected NYSE-traded contract research organization with 8,500 employees specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries.
"HemaXellerate is a stem cell-based cellular therapy. At Regen safety of patients is our first priority. We are thankful to the FDA for discussing and advising us on our safety studies, which will ensure we deliver a high quality product to patients with aplastic anemia, who currently have no other therapeutic options," said David Koos, Chairman and CEO of Regen BioPharma. "Subsequent to receiving the audited toxicology report in mid-September, we plan to respond to the FDA with the results of the toxicology study. Once reviewed by the FDA, we anticipate being in a position to initiate our 10 patient clinical trial."
HemaXellerate is a personalized stem cell therapy that stimulates production of blood cells from the bone marrow of patients. Regen is planning to utilize HemaXellerate to treat patients with aplastic anemia, a condition associated with reduced ability of the bone marrow to make blood. The Company's CEO also stated, "If successful, the Company may expand into other conditions such as poor blood production associated with chemotherapy which is a potential multibillion dollar per year market."
Rgbp $$$$$ news out
Regen BioPharma, Inc. Successfully Completes in Life Portion of Experiments Requested by FDA for HemaXellerate Pre-Clinical Study
Company anticipates pre-clinical study to lead to clearance of its Aplastic Anemia Therapy (IND # 15376) for clinical trials
PR Newswire Regen BioPharma, Inc.
50 minutes ago
SAN DIEGO, California, Jul. 21, 2015 /PRNewswire/ -- Regen BioPharma Inc. (RGBP) and (RGBP) announced today positive preliminary safety results from the in life portion of an experimental study requested by the US Food and Drug Administration (FDA) assessing toxicity in mice treated with high doses of HemaXellerate, a proprietary therapy under development by Regen Biopharma, Inc. After a 14 day observation period, male and female mice administered with higher than 10-fold the proposed human dose on a per kilogram basis exhibited no adverse effects. Regen expects to receive an audited report on full completion of the experiments in mid-September.
"The fact that no adverse effects related to HemaXellerate administration were observed during the in life portion of this study, even at extremely high doses, in my opinion is a very strong confirmation of the safety of our product," said Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma. "We are impressed with the diligence, expedience, and thoroughness that Charles River Laboratories exhibited in conducting this study."
The experiment is being conducted under Good Laboratory Practices (cGLP) by Charles River Laboratories. Charles River Laboratories, established in 1947, is a well respected NYSE-traded contract research organization with 8,500 employees specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries.
"HemaXellerate is a stem cell-based cellular therapy. At Regen safety of patients is our first priority. We are thankful to the FDA for discussing and advising us on our safety studies, which will ensure we deliver a high quality product to patients with aplastic anemia, who currently have no other therapeutic options," said David Koos, Chairman and CEO of Regen BioPharma. "Subsequent to receiving the audited toxicology report in mid-September, we plan to respond to the FDA with the results of the toxicology study. Once reviewed by the FDA, we anticipate being in a position to initiate our 10 patient clinical trial."
HemaXellerate is a personalized stem cell therapy that stimulates production of blood cells from the bone marrow of patients. Regen is planning to utilize HemaXellerate to treat patients with aplastic anemia, a condition associated with reduced ability of the bone marrow to make blood. The Company's CEO also stated, "If successful, the Company may expand into other conditions such as poor blood production associated with chemotherapy which is a potential multibillion dollar per year market."